Thursday, November 18, 2010 4:15:47 PM
It is not just about current shareholders. Shouldn't the point be for the technology to move forward?
Look, let them demonstrate something in sleep apnea. This is a major indication and could prove to be a huge windfall for current shareholders. They need a few weeks for data cleanup. Fine. But more distressing for longs is the failure to rapidly come up with an oral form of CX1739, to file an IND for a small scale phase IIa ADHD trial, to rapidly prove proof of principle.
Now we are at the vage whim of "waiting for input" on the trial design by some entity. Whatever that means. Yes. I'm sure the company could fairly easily raise 1.5 to 3 million dollars by printing new warrants with new strike prices, further diluting the company. But it will not advance anything.
One might argue the following for increasing shareholder wealth. 1. let's see what they come up with with sleep apnea. 2. Should this fail or not lead to meaningful pharma interest, can they find away to fund an ADHD trial through a partner or other funding. I will not even get into my jaundiced viewpoint of Cortex being able to rapidly complete said ADHD trial.
But sleep apnea is a flop, or leads to ambiguous, uncertain results which does not elicit pharma interest. And if there is no suitor being able to move the pen onto the paper in the near future to fund an ADHD trial. Might this be a good time to sell the company? Maybe we can get 50 cents for the assets, turning them over to somebody with the money to develop them. It would seem that all parties would benefit.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM